Back to top
more

Fortress Biotech, Inc. (FBIO)

(Real Time Quote from BATS)

$3.64 USD

3.64
479,677

+0.27 (8.01%)

Updated Jan 19, 2021 12:47 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 16% (213 out of 253)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for FBIO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Fortress Biotech, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents NA 137 83 153 92
Receivables NA 14 8 17 9
Notes Receivable NA 0 0 0 0
Inventories NA 1 1 0 0
Other Current Assets NA 4 20 13 9
Total Current Assets NA 156 111 183 110
Net Property & Equipment NA 12 12 10 7
Investments & Advances NA 11 0 1 1
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 7 1 34 36
Deposits & Other Assets NA 18 16 18 16
Total Assets NA 226 141 246 171
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable NA 7 19 13 2
Accounts Payable NA 35 34 36 24
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 10 12
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 1 2 8 18
Total Current Liabilities NA 46 56 67 57
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 10 4
Long-Term Debt NA 77 60 43 23
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 7 5 5 5
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 154 121 125 88
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 0
Capital Surplus NA 462 397 364 284
Retained Earnings NA -436 -396 -312 -245
Other Equity NA 46 18 68 44
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 73 20 121 83
Total Liabilities & Shareholder's Equity NA 226 141 246 171
Total Common Equity 0 73 20 121 83
Shares Outstanding 93.70 70.70 56.60 50.60 48.80
Book Value Per Share 0.00 1.03 0.35 2.38 1.70

Fiscal Year End for Fortress Biotech, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Assets          
Cash & Equivalents NA 218 183 136 137
Receivables NA 17 12 18 14
Notes Receivable NA 0 0 0 0
Inventories NA 1 1 1 1
Other Current Assets NA 2 3 5 4
Total Current Assets NA 238 200 159 156
Net Property & Equipment NA 12 12 13 12
Investments & Advances NA 12 11 11 11
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 11 7 7 7
Deposits & Other Assets NA 3 18 18 18
Total Assets NA 296 269 229 226
Liabilities & Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Notes Payable NA 0 22 15 7
Accounts Payable NA 33 32 34 35
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 33 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 3 2 1 1
Total Current Liabilities NA 37 57 52 46
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 51 64 71 77
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 7 7 7
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 120 152 153 154
Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 1 1 1
Capital Surplus NA 574 521 485 462
Retained Earnings NA -477 -462 -449 -436
Other Equity NA 79 56 38 46
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 176 117 75 73
Total Liabilities & Shareholder's Equity NA 296 269 229 226
Total Common Equity 0 176 117 75 73
Shares Outstanding 93.70 88.00 82.40 81.30 70.70
Book Value Per Share 0.00 2.00 1.42 0.93 1.03